

Visual Hallucinations in the Psychosis Spectrum and Comparative Information From Neurodegenerative Disorders and Eye Disease

Flavie Waters^{*.1,2}, Daniel Collerton³, Dominic H. ffytche⁴, Renaud Jardri⁵, Delphine Pins⁵, Robert Dudley^{6,7}, Jan Dirk Blom^{8,9}, Urs Peter Mosimann¹⁰, Frank Eperjesi¹¹, Stephen Ford¹², and Frank Larøi¹³

¹Clinical Research Centre, Graylands Hospital, North Metropolitan Health Service Mental Health, Perth, Western Australia, Australia; ²Centre for Clinical Research in Neuropsychiatry, School of Psychiatry and Clinical Neurosciences, the University of Western Australia, Perth, Western Australia, Australia; ³Northumberland, Tyne and Wear NHS Foundation Trust, Bensham Hospital, Gateshead and Newcastle University, Newcastle Upon Tyne, UK; ⁴Institute of Psychiatry, King's College London, London, UK; ⁵Laboratoire de Neurosciences Fonctionnelles & Pathologies, Université Droit & Santé (UDSL), Univ Lille Nord de France and Centre Hospitalier Universitaire (CHU Lille), Hôpital Fontan, Lille, France; ⁶School of Psychology, Newcastle University, Newcastle Upon Tyne, UK; ⁷South of Tyne Early Intervention in Psychosis Service, Northumberland, Tyne and Wear NHS Foundation Trust, Newcastle Upon Tyne, UK; ⁸Parnassia Psychiatric Institute, The Hague, The Netherlands; ⁹Department of Psychiatry, University of Groningen, Groningen, The Netherlands; ¹⁰University Hospital of Old Age Psychiatry, University of Bern, Bern, Switzerland; ¹¹Ophthalmic Research Group, School of Life and Health Sciences, Aston University, Birmingham, UK; ¹²Department of Psychiatry, Sir Charles Gairdner Hospital, North Metropolitan Health Service Mental Health – Older Adult Program, Perth, Western Australia, Australia; ¹³Department of Psychology: Cognition and Behaviour, University of Liège, Liège, Belgium

*To whom correspondence should be addressed; Clinical Research Centre, Graylands Hospital, Private Mail Bag 1, Mount Claremont 6010, Perth, Western Australia, Australia; tel: (+61 8) 6346 6650, fax: 9384 5128, e-mail: Flavie.waters@health.wa.gov.au

Much of the research on visual hallucinations (VHs) has been conducted in the context of eye disease and neurodegenerative conditions, but little is known about these phenomena in psychiatric and nonclinical populations. The purpose of this article is to bring together current knowledge regarding VHs in the psychosis phenotype and contrast this data with the literature drawn from neurodegenerative disorders and eye disease. The evidence challenges the traditional views that VHs are atypical or uncommon in psychosis. The weighted mean for VHs is 27% in schizophrenia, 15% in affective psychosis, and 7.3% in the general community. VHs are linked to a more severe psychopathological profile and less favorable outcome in psychosis and neurodegenerative conditions. VHs typically co-occur with auditory hallucinations, suggesting a common etiological cause. VHs in psychosis are also remarkably complex, negative in content, and are interpreted to have personal relevance. The cognitive mechanisms of VHs in psychosis have rarely been investigated, but existing studies point to source-monitoring deficits and distortions in top-down mechanisms, although evidence for visual processing deficits, which feature strongly in the organic literature, is lacking. Brain imaging studies point to the activation of visual cortex during hallucinations on a background of structural and connectivity changes within wider brain networks. The relationship between VHs in psychosis, eye disease, and neurodegeneration remains unclear, although the pattern of similarities and differences described in this

review suggests that comparative studies may have potentially important clinical and theoretical implications.

Key words: visual hallucinations/schizophrenia/psychosis/cognition/imaging

Introduction

Hallucinations are defined in different ways by different philosophical traditions.¹ In the clinical domain, a visual hallucination (VH) is a visual percept, experienced when awake, which is not elicited by an external stimulus. It contrasts with a visual illusion which is elicited by an external stimulus but differs from the percept normally associated with the stimulus. VHs occur in a wide-range of organic and psychiatric conditions, as well as in the absence of any demonstrable pathology. These experiences have been well described and researched in the context of organic disorders, particularly eye disease and neurodegenerative conditions such as dementia with Lewy bodies (DLB) and Parkinson's disease (PD), but VHs have been largely neglected in psychiatric disorders and delirious states and in nonclinical populations.

Although the diagnostic manuals for mental disorders list hallucinations as a primary characteristic symptom in psychotic disorders, *auditory* hallucinations are the symptoms that clinicians commonly ask about. One explanation lies in the traditional beliefs that VHs are more

common in organic states than in psychosis.² It is also often difficult to decide whether the full criteria for the presence of VHs have been fulfilled when a range of other perceptual abnormalities are reported.

In this article, we review the available evidence with regards to the prevalence, phenomenology, clinical characteristics, and assessment methods for VHs in the psychosis spectrum alongside studies of cognition, brain imaging, electrophysiology, and treatment (cognitive behavioral and pharmacological). Given the lack of available literature on other psychiatric disorders, our focus is on schizophrenia, affective psychosis (ie, bipolar and depressive disorders), and nonclinical population groups (who experience VHs outside of the context of any psychiatric or somatic disease). The psychosis evidence is compared with evidence related to eye and neurodegenerative disease in the hope that similarities and differences between different clinical contexts will help our understanding of the underlying mechanisms of VH and its treatment.

To our knowledge, this is the first review of VH in psychosis. For the first time, a cross-disciplinary and cross-diagnostic examination of VH is also presented. Our broad aim is to provide a useful base for future studies on the topic and specifically to achieve a clearer understanding of VH in psychiatric illness and greater clarity regarding the assessment of VH for use in clinical practice and research.

Parts of this article were presented in Durham at the 2nd International Consortium on Hallucination Research (ICHR) 2013 conference.³

Epidemiology

Psychosis

The centrality of VH in psychosis has been put into question by studies which show that auditory, and not visual, hallucinations are among the cardinal symptoms of schizophrenia which are common in all cultures.⁴ VHs, however, appear to be more frequent in schizophrenia than commonly thought.

Table 1 describes studies that have provided the point prevalence of VH in schizophrenia. Estimates vary widely from 4% to 65%, reflecting variations in population and ascertainment methods. Out of 29 studies that have addressed this issue (5873 participants), the weighted mean prevalence of VH in schizophrenia is 27% (SD = 9). For comparison, the weighted mean of auditory hallucinations as provided by the same studies is 59% (range: 25%–86%; SD = 15), ie, twice as frequent as VH, although it is possible that clinician biases toward auditory hallucinations have skewed the results.

Psychotic symptoms such as hallucinations and delusions are also a common feature of affective disorders including bipolar disorder.⁶ Table 2 shows that out of 12 studies that differentiated between different modalities

of hallucinations, the weighted mean frequency of VH is approximately 15% (range: 6%–27%, SD = 9). Similarly to schizophrenia, the rates of VH in bipolar disorder are approximately half that of auditory hallucinations (28%).

Overall, these data challenge the assumption that VHs are atypical or uncommon in psychosis.

Subclinical Symptoms in the General Community

Occasional hallucinatory experiences are fairly common in community-living individuals. However, community and epidemiological studies rarely report the prevalence rates for VH specifically and independently from other hallucinatory experiences, with few exceptions. Table 3 (A) shows that the weighted mean for VH in the general community is 7.3% (SD = 5, based on 6 studies).

Little is known about what distinguishes visual hallucinators from non-hallucinators in the general population, but evidence suggests that factors such as intoxication and withdrawal from substances such as alcohol, cannabis and cocaine, and other physical states such as physical illness and stress are linked to VH.^{46,47} Importantly, when research criteria exclude hallucinations arising from drug-taking or physical illness, the weighted percentages of hallucinations in the community reduce to 6% (see table 3, B).

Eye Disease and Neurodegenerative Conditions

For comparison, it is helpful to understand the epidemiology of VH in other disorders in which VHs are common. The frequency estimates for VH in PD range from 15% to 40% (comparable to those in psychosis), and the frequency roughly doubles for PD dementia (PDD) (30%–90%) and DLB (60%–90%).^{48,49} In age-related eye disease, between 10% and 60% of patients experience complex VH, depending on the severity of visual loss. The most common eye disease associated with VH is age-related macular degeneration.^{50,51} VHs are the diagnostic criterion for Charles Bonnet syndrome (CBS). Such observations have prompted many authors to suggest that VH arise because of dysfunctions involving visual processing.

Demographic and Clinical Characteristics

Gender

Contradictory data have emerged regarding a VH gender pattern in psychosis or organic illness.^{5,37,52,53} By contrast, studies in PDD and DLB do not report different frequencies of VH by gender, although it is important to consider the gender ratio in these disorders which are more common in men than women.

Age Risk Factor and Longitudinal Course

With regards to age as a risk factor for VH in psychosis, some studies have demonstrated evidence that VH are

Table 1. The Comparative Point Prevalence of Visual and Auditory Hallucinations in Schizophrenia

Authors	n	Modality of Hallucinations	
		Visual (%)	Auditory (%)
Bowman and Raymond (1931) ⁵	1408	22	53
Arnold (1949) ⁶	^a	14	78
Feinberg (1962) ⁷	19	4	84
Malitz et al (1962) ⁸	100	9	50
Vitols et al (1963) ⁹	110	13	35
Goldberg et al (1965) ¹⁰	270	18	45
Mott et al (1965) ¹¹	50	24	66
Small et al (1966) ¹²	50	30	66
Chapman (1966) ¹³	^a	40	^a
Holmboe and Astrup (1967) ¹⁴	255	25	79
Jansson (1968) ¹⁵	293	13	25
Goodwin et al (1971) ¹⁶	45	59	82
Eggers (1973) ¹⁷	^a	44	71
McCabe (1976) ¹⁸	40	20	36
Young (1974) ¹⁹	20	45	^a
Zarroug (1975) ²⁰	69	47	62
Ciampi and Müller (1976) ²¹	^a	18	58
McCabe (1976) ¹⁸	25	20	52
Deiker and Chambers (1978) ²²	28	64	86
Huber (1979) ²³	^a	33	75
Ndeti and Singh (1983) ²⁴	51	43	43
Ndeti (1984) ²⁵	141	15	41
Winokur et al (1985) ²⁶	140	32	78
Phillipson and Harris (1985) ²⁷	73	62	44
Bracha et al (1989) ²⁸	43	56	42
Owens and Slade (1989) ²⁹	^a	29	63
Mueser et al (1990) ³⁰	117	14	71
Jablensky et al (1992) ⁴	1288	30	55
Bauer et al (2011) ³¹	1238	34	79
Total: 29 studies, n = 5873 participants		Weighted mean = 27% SD = 9.73	Weighted mean = 59% SD = 15.30

Note: ^aNot assessed or missing data.

Table 2. The Comparative Prevalence of Visual Hallucinations and Auditory Hallucinations in Bipolar and Affective Disorder

Authors	n	Diagnosis	Modality of Hallucinations	
			Visual (%)	Auditory (%)
Bowman and Raymond (1931) ⁵	1009	Mania	9	17
Rosenthal et al (1966) ³²	79	Mania	21	30
Winokur (1969) ²⁶	100	Mania	9	21
Goodwin et al (1971) ¹⁶	28	Primary affective disorder	72	82
Taylor and Abrams (1975) ³³	52	Mania	23	47
Rosenthal et al (1980) ³⁴	32	Mania	25	30
Winokur (1984) ²⁶	122	Bipolar disorder	9	14
Black and Nasrallah (1989) ³⁵	467	Acute bipolar disorder	6	13
Mueser et al (1990) ³⁰		bipolar disorder	25	75
	37	Severe affective disorder	10	17
Keck et al (2003) ³⁶	352	Mania	22	25
Baethge et al (2005) ³⁷	33	Manic/mixed type with hallucinations	27	54
	32	Depressed type with hallucinations	25	59
Tillman et al (2008) ³⁸	549	BPD	26	57
Total: 12 studies, n = 2892			Weighted mean = 15% SD = 9.75	Weighted mean = 28% SD = 18.11

Note: BPD = bipolar disorder.

Table 3. The Comparative Prevalence of Visual Hallucinations and Auditory Hallucinations in the General Community (A) and After Excluding Hallucinations Arising From Drug-Taking or Physical Illness (B)

	<i>n</i>	Visual Hallucinations (%)
(A) General population		
Eaton et al (1991) ³⁹	810	8
Tien (1991) ⁴⁰	18 572	14
Ohayon (2000) ⁴¹	13 057	3.2
Waters et al (2003) ⁴²	562 (university students)	10
Larøi and Van der Linden (2005) ⁴³	236 (university students)	32
Kessler et al (2005) ⁴⁴	9282	6.3
	Total: 6 studies, <i>n</i> = 42 519	Weighted mean = 7.35% SD = 5.08
(B) Excl drug-taking and physical illness		
Eaton et al (1991) ³⁹	810	4
Tien (1991) ⁴⁰	18 572	7
Van Os et al (2000) ⁴⁵	7076	2–6
	Total: 3 studies, <i>n</i> = 26 458 participants	Weighted mean = 6% SD: 1.73

more common in younger, compared with older, individuals with schizophrenia,^{31,53} although negative findings exist.¹⁶ A similar inconsistency is found in the eye disease literature with only 3 of 9 studies investigating age and VHs reporting a weak association.⁵¹

By contrast, in nonclinical populations, the prevalence of VH is maximal in adolescence, and late adulthood, between which times the frequencies decrease.^{40,54} One explanation for increased frequency of VH with age is that the prevalence of most chronic disorders increases with age, as does the prevalence of neurodegenerative disorders and age-related eye disease. In further support, the prevalence of death-bed visions among the dying may be as high as 50%.⁵⁵

Thus, there appears to be a bimodal distribution of VH in the population with one peak in late adolescence and early adulthood, which is associated with psychosis, and a second increase in late life associated with eye and brain disease.

With regards to the longitudinal course, it is believed that hallucinations in schizophrenia tend to decrease as individuals age,⁵⁶ although it is important to note that the risk of schizophrenia also declines with age.

Clinical Characteristics of VH

The presence of VH in psychosis has often been linked to a more severe psychopathological profile^{30,57} and to a less favorable prognosis.¹⁸ In patients with bipolar disorder, Baethge et al³⁷ found that hospitalization for individuals with hallucinations (all modalities) averaged 17% longer than those who did not hallucinate.

In the general community, a link between VH and anxiety (OR = 5.0)^{41,58} and psychotic pathology (OR = 6.6)⁴¹ has been reported. The important role of negative emotions in VH is illustrated in studies showing that stress and bereavement are linked to VH. For example,

hallucinations of a dead spouse are common grief reactions in older adults.⁵⁹

The literature in neurodegenerative disease is consistent with this view of greater psychopathology in VH, with studies showing poorer response to treatment, greater mortality and morbidity, major depressive syndrome, and a move to institutional care.^{60,61}

Thus, in both younger patients with psychosis and older patients with neurodegenerative disease, VHs are associated with poorer functioning and outcome. The same is not true of eye disease (eg, CBS) where the symptoms improve over time without progressive loss of cognitive function.

Association With Other Symptoms

In schizophrenia, VHs typically co-occur in association with other hallucinations and other sensory modalities.^{16,28,30,62} For example, it has been reported that co-occurring visual and auditory hallucinations occur in up to 84% of individuals with schizophrenia.³⁰ Furthermore, early evidence suggested VH never occurred in psychosis without the presence of auditory hallucinations (either at the same time—multimodality hallucinations— or on different occasions).⁶² In Oorschot et al’s⁵⁷ sample of individuals with mixed psychosis, VHs occurring alone were rarer than auditory hallucinations occurring alone. As shown in table 1, auditory hallucinations predominate over VH in terms of their relative prevalence.

Hallucinations in multiple modalities have also been noted in individuals with severe depression⁶³ and with mixed psychiatric diagnoses,⁶⁴ as well as in nonclinical adults and adolescents (*n* = 355, 11–13 years).⁶⁵ Such co-occurrences of auditory/VHs suggest a common hallucinatory mechanism which, in combination with specific sensory dysfunctions, determines the modality of hallucinations.

It is important to note, however, that “simultaneous” (or “fused”) auditory and VHS are not a frequent occurrence.¹⁶ In most cases, they are experienced at different times (eg, an auditory hallucination one day and a VH the next). Furthermore, when simultaneous auditory/VHS do occur, they are typically unrelated⁶⁶ (eg, seeing the devil while hearing the voice of a relative inside one’s head), suggesting that the mechanisms for auditory and VHS in these disorders must be partly independent, though with some overlap.

By contrast, a different pattern can be observed in organic disease. In PD, VHS predominate over auditory hallucinations,⁶⁷ and in CBS, the absence of hallucinations in other modalities is a diagnostic criterion. Where eye disease co-occurs with dementia, auditory hallucinations and delusions may appear as the dementia progresses, as is the case in PD⁶⁸ or dementia alone.⁶⁹ In these disorders, auditory and VHS very rarely occur at the same time.

Overall, the relative proportion of auditory to visual modality hallucinations seems to differentiate the psychosis spectrum from organic conditions.

Phenomenological Features of VH

Psychosis

There are few systematic or comprehensive studies of VH as dimensional experiences in psychosis. Exceptions include Goodwin et al,¹⁶ Gauntlett and Kuipers,⁶⁴ and Dudley et al.⁷⁰ For the following review, information was drawn from these and other studies.^{12,16,28,53,62,71,72}

Perceptual Qualities. VHS in psychosis are reported to have the physical properties of real perceptions. They are often life-sized, detailed, and solid. They are projected into the external world in most cases and are typically “anchored in external space,” either just beyond the reach of individuals or further away. VHS often have 3 dimensional shapes, with depth and shadows, and distinct edges. VH can be colorful or in black and white. Images are often described as dynamic with the contents changing in size, shape, and movement but may also be static.

Temporal Aspects. The frequency of hallucinatory episodes varies from rare to frequent, and episodes can last several seconds to several minutes. VH may be experienced during both day and night.

Content. Fully formed VHS are more common than unformed visual experiences and distortions. Complex VHS often comprise images of people (walking, family), faces, animals, objects, or events (eg, visions of fires) taking place in front of the individual. In contrast to hallucinations in organic conditions, a common theme is of visions with frightening content (bugs, dogs, snakes, distorted faces), and these are linked to distress. Unlike VH

in PD, visions of dead people are rare, although visions of God, angels, the devil, saints, and fairies are common.

Reality. VHS are perceived to be real and “definitely present” in a concrete sense. In further support for the subjective reality of the experience, a majority of individuals undertake some activity directly related to the vision—such as moving toward the vision, hitting at the vision, or moving away. In the case of distressing images, individuals may act to keep themselves safe.

Sense of Control. A lack of control over the content and appearance is a prominent feature of VH in psychosis. Individuals are surprised when VHS occur and are generally helpless to change or stop them. In general, individuals believed that visions are experienced only by themselves.

Onset and Triggers. The onset of VH has been linked to stress, tiredness, loneliness, and relationship problems in psychiatric individuals. Other psychological triggers include negative emotions, and they may co-vary with levels of anxiety.

Reactions. A mixture of positive and negative images may be experienced. Reactions vary and can include pleasure, happiness and reassurance, or indifference. Images can also evoke fright, depression, sadness, or hopelessness. While the *content* of VH is often impersonal or unrelated to the person, images are often interpreted to have personal implications. Many individuals believe that the content of visions must be acted upon, for fear of a negative event occurring as a consequence. This differs from hallucinations in organic conditions, where VHS are not generally perceived to be real.

Beliefs and Appraisals. VHS may be believed to arise from an external source, particularly of supernatural origin. Images of powerful religious figures are often perceived to be visions intended as a sign for the person to act and as a threat to their physical or psychological wellbeing. This can also impact on the individual’s belief system and can be used as evidence for their delusional beliefs.

Overall, such rich phenomenology of VH in psychosis points to true hallucinatory experiences and not only misperceptions. This close examination of VH characteristics also reveals remarkable similarities with auditory hallucinations with regards perceptual quality, contents, lack of control, beliefs, appraisals, and reactions.

With regards a comparison with organic disorders, broadly speaking, the form and character of VH in psychosis is similar to those seen in eye disease and neurodegeneration. Although there is a notable lack of studies making direct comparisons, there are several characteristics that distinguish VH in psychotic disorders from

other disorders, namely frightening contents, emotional reactions, and appraisals of personal significance; a lack of illusions (common in neurodegenerative disease) and simple VHs (common in eye disease) also differ.

Subclinical Symptoms in the General Community

Nonclinical individuals in the community report vivid VH, where objects are real and uncontrollable, but often of brief duration.⁷³ The features of VH in nonclinical samples are broad-ranging and include unformed VH (such as dots, flashes of light and other unformed shapes) and formed VH (people and faces, but also aliens).⁶⁵ In contrast to VH in psychosis, hallucinated images in non-clinical populations are less likely to involve complex scenes but more likely to show people.⁵²

These VH clinical features are similar to that of auditory hallucinations in nonclinical populations, which also tend to be brief and mostly neutral or pleasant in content.⁷⁴

Eye Disease and Neurodegenerative Conditions

For comparison with the above, the most detailed accounts of visual content are found in the eye disease literature (CBS).⁷⁵ The commonest contents are of simple hallucinations, followed by images of people or animals (50%–80%), patterns (55%), faces often described as

grotesque and cartoon-like (40%), landscapes or inanimate objects (20%). They are usually colorful. Unlike in psychosis, VHs in CBS are not generally perceived to be real or to have personal meaning. Only in a third of the cases is the content negative. Once individuals understand they are a common feature of poor vision, anxiety about VH generally decreases. This differs from psychosis, where lack of insight may contribute to distress about these experiences. Other dimensional features related to clarity, frequency, temporal factors, and appearance are similar to those in psychosis.⁷⁶ In PD, VHs mostly consist of people who may be familiar or not, and alive or deceased (73%), animals (33%), and objects (19%) which may appear briefly and move sideways (passage hallucination).⁴⁹ The contents are fairly stereotyped and repetitive but may last for hours at a time. Experiences appear to be real and outside voluntary control but are not often perceived as frightening. In dementia, VHs tend to be of fairly mundane content, including unfamiliar or small figures, faces, animals, and objects/machines, and are rarely distressing.⁶⁹

Figure 1 (adapted from ffytche⁷⁷) provides an overview of VH in different clinical settings, where a range of clinical conditions (columns) are cross-tabulated with VH content and related phenomena (rows). Comparing the phenomenology of VH in psychosis with other conditions suggests that they are most similar to VH in cortical




Fig. 1. Visual perceptual symptoms and their clinical contexts.⁷⁷ A range of clinical conditions (columns) are cross-tabulated with visual hallucination (VH) content and related phenomena (rows). For each condition, the percentage of individuals with VHs reporting a given content is coded red (>20%), pink (10%–20%), or white (not reported or < 10%). The prevalence of each symptom in psychosis is taken from.⁶⁴ For auditory hallucinations, (+) indicates higher prevalence than VH and (–) indicates lower prevalence than VH (figure adapted from ffytche⁷⁷). Visual experiences in schizophrenia best match the phenomena reported in the red box derived from PD, AD, DLB, and peduncular lesions—but not the green (eye and visual pathway pathology) and blue (serotonergic syndrome) boxes.

and subcortical disorders (red box) but differ in the relative predominance of auditory and VHS. Whether this is an important neurobiological distinction is unclear, and the boundary of the grouping has been left open as indicated by the dashed line.

The Assessment of VHS

It is often difficult to distinguish VH from related visual phenomena such as illusions, distortions, and misperceptions that co-occur with VH in psychosis and other conditions. The relationship between what is seen and what is actually present in the environment is complex and poorly understood with internal models and top-down inference interacting with visual inputs. The match between what is perceived and what is present is closest for veridical perception (our day-to-day visual perceptual experience), tenuous for illusions, and absent for hallucinations; however, there are no sharp dividing lines between categories. Based on a working definition of hallucinations,⁷⁸ the key features to elicit in an assessment of VH are (see [Box 1](#)):

1. They must be experienced in full consciousness (rules out sleep-related VH, fever, delirium, and hypnosis).
2. Not elicited by an external stimulus (excludes visual distortions and illusions).
3. The experience has a sense of reality to resemble a veridical perception (must have physical properties of real perceptions and be located in external space; note that this does not mean that VH must be perceived to be real or that insight must be lacking).
4. The subject does not feel s/he has direct and voluntary control (rules out visual imagery).

Cognition

Cognitive processes of VH in psychosis have rarely been investigated. In organic disorders, hallucinations are held to reflect disorders within distributed perceptual systems. The Perceptual and Attentional Deficit model advocates for a combination of impaired visual processing and attention in VH in neurodegenerative disorders and eye disease.⁸⁰ Diederich et al's⁸¹ contemporaneous PD-developed interactive model similarly proposes a combination of poor visual input and processing with defective central visual monitoring. More recently, Shine et al's Attentional model⁸² proposes that hallucinations occur in PD when there is underactivity in dorsal attentional networks in the presence of ambiguous percepts. Each of these models, therefore, proposes that combined attentional and visual perceptual problems lead to VH.

In psychosis, however, perceptual processes are usually believed to be intact or even overactive. It has been suggested that VH in psychosis may be best understood in terms of the intrusion into awareness of subconscious images or highly vivid mental imagery, as modulated by

Box 1. A Diagnostic Algorithm for Visual Hallucinations and Related Phenomena⁷⁹

Question 1: Are the visual phenomena experienced (a) during sleep, (b) on the border of waking and sleeping, or (c) while awake?

a) During sleep

Rule out: dream

Possibility 1: incubus phenomenon

Possibility 2: visual sleep start

b) On the border of waking and sleeping

Possibility 1: hypnagogic hallucination

Possibility 2: hypnopompic hallucination

c) While awake

Go to Question 2

Question 2: Are the visual phenomena perceptual in nature? (ie, with physical properties comparable with sensory perceptions)

No Rule out: imagery

Yes Continue with Question 3

Question 3: Do they constitute (a) images without a representation in the outside world, (b) images with a representation in the outside world, or (c) distortions?

a) Without representation in the outside world (visual hallucinations):

Go to Question 4

b) With a representation in the outside world (visual illusions):

Go to Question 5

Distortions (metamorphopsias):

Go to Question 6

Question 4: Are the hallucinations (a) simple in nature, (b) geometric, (c) complex, or (d) compound (ie, multimodal) in nature?

a) Simple hallucinations

Rule out: physiological phenomena such as blue-field entoptic phenomenon, macular star pattern, or mouches volantes (uncomplicated)

Determine: type and context

b) Geometric hallucinations

Determine: type and context

c) Complex hallucinations

Determine: type and context

d) Compound hallucinations

Determine: type (ie, sensory modalities) and context

Question 5: Are the illusions attributable to (a) physical reality, (b) the perceptual system, or (c) mental associations?

a) Physical illusions

Determine: type and context (never pathological!)

- b) Physiological illusions
Determine: type and context
- c) Cognitive illusions
Determine: type and context

Question 6: Do the distortions have (a) a peripheral or (b) a central origin?

- a) Peripheral metamorphopsias
Determine: type and context
- b) Central metamorphopsias
Determine: type and context

personal, social, or psychological variables.⁵⁸ In support, an increase in the salience of imagery has been found in schizophrenia individuals with VH.⁴⁵ Other cognitive deficits found in psychotic VH include source-monitoring impairments, such as difficulties making internal/external and self/other discriminations⁸³ and confusion regarding whether the source of material was real or imagined.⁸⁴ Such source-monitoring deficits are also commonly found in auditory hallucinations⁸⁵ and may lead to these events being believed as real.

Personal, social, and cultural contributors to VH have not yet been systematically investigated, although top-down mechanisms (which include expectations, personal meaning-making, and social context) may influence dynamic attentional processes by biasing the competition between potential perceptions toward objects and persons that have personal and social relevance. In support for this view, stress and bereavement are linked to the onset of VH. Further support comes from cognitive models of psychosis⁷⁸ that propose that key influences of personal events, social/cultural context, and expectations have the ability to activate percepts in the absence of external stimulation.

Altogether, mechanisms of VH in psychosis are not well understood. Interesting similarities with the literature on auditory hallucination exist, including source-monitoring deficits and the strong influence of top-down mechanisms. By contrast, evidence for visual processing difficulties which feature strongly in models of VH in the organic literature⁷⁷ is lacking.

Brain Imaging and Electrophysiology

In the field of psychosis, a study conducted in individuals with first-episode psychosis ($n = 15$ with VH) showed per-hallucinatory activity within visual association cortex, while the vividness of VH was linked to activity within the primary visual cortex.⁸⁶ Activity in the visual association cortex during VH has also been demonstrated in single case studies in schizophrenia.^{87,88} Concerning the organic literature, dysfunctions of higher visual processing areas during or between VH episodes have been found

in Alzheimer's disease,⁸⁹ DLB,^{90,91} and CBS⁹² within the ventral and the dorsal visual pathways involved in object recognition and visuospatial memory^{93,94} as well as the frontal lobes.⁹⁵ Furthermore, structural changes in these areas were independent of cognitive function and age.⁹⁶ Overall, symptom-capture studies in these populations showed that the location of the per-VH activity correlated with the phenomenological content of the hallucinatory experiences (ie, color-specialized cortex if in color, face-specialized cortex if faces are experienced, etc).

Connectivity studies have much relevance for the study of VH, given that dysconnectivity is a prominent model for psychosis, which could also apply to specific symptoms such as hallucinations.⁹⁷ The dysconnectivity hypothesis suggests that the existence of impaired connectivity between different brain regions is responsible for abnormal functional integration within neural networks. In support for dysconnectivity, using diffusion tensor imaging, Ashtari and collaborators showed that adolescents suffering from early-onset schizophrenia with a history of VH exhibited lower fractional anisotropy, potentially reflecting a loss in white matter integrity, in the left inferior longitudinal fasciculus which connects temporal and occipital cortices, when compared with individuals without VH.⁹⁸

The hippocampal complex (HC) is also of considerable interest with regards to VH in both neurodegeneration and psychosis. The HC has been shown to be atrophied in individuals with PD and VH,⁹⁹ and it appears to occupy a key place within the networks involved in VH in psychosis.¹⁰⁰ For example, a recent multimodal connectivity study, combining functional connectivity, tract-based spatial statistics, and shape analysis of the HC, confirmed differential connectivity patterns of this structure in individuals with schizophrenia. Moreover, this abnormal connectivity depends on the sensory-modality of hallucinatory experiences involved and was particularly obvious with visual areas in patients with VH.⁹⁷ In addition, a symptom-capture study of VH in schizophrenia⁸⁷ reported cortical activity in the HC, although this was not reported in CBS.⁹²

A particular subtype of functional connectivity studies focuses on spontaneous fluctuations at rest. It has already been used in the field of auditory hallucinations to test the hypothesis of disrupted intrinsic connectivity as a pathological mechanism.¹⁰¹ Jardri and colleagues' study confirmed a dynamic interaction between association sensory cortices and the default-mode network (DMN) for patients with multisensory hallucinations, including VH.⁸⁶ Sensory and DMN networks were found to be anticorrelated during the experience of hallucinations; furthermore, the DMN spatial and temporal instability persisted during non-hallucinatory periods.⁸⁶ Impaired interactions with the DMN have also been suggested in the pathophysiology of VH in PD,⁸² but contrary to what has been proposed in first-episode psychosis in which the DMN seems primarily

and intrinsically affected, these authors proposed an external DMN interference through aberrant interactions with ventral and dorsal attentional networks.

Fewer studies have investigated the electrophysiology of VH. Spencer and colleagues found reduced visual cortex activation as measured by a negative evoked potential component (NI) and increased gamma band phase locking associated with VH in schizophrenia, consistent with an underlying visual cortical hyperexcitability and reduced responsiveness to external visual stimulation in this subgroup.¹⁰² Indices of hyperexcitability and reduced responsiveness have also been found in PD (a delayed P100 evoked potential component)¹⁰³ and post-lysergic acid diethylamide VH (occipital theta coherence).¹⁰⁴ The electrophysiology of VH capture is consistent with brain imaging studies in suggesting activation of visual association cortex as measured by coherence¹⁰⁵ or theta/alpha desynchronization.¹⁰⁶

Comparative Psychopathology

What are the implications of the similarities and differences between VH in psychosis spectrum, eye and neurodegenerative disease outlined above? It is clear that there is an absence of evidence in many areas, and that direct comparative work is required. VHs in psychosis most closely resemble VH in neurodegeneration, and the association of auditory and VHs in these conditions suggests the 2 modalities of hallucination share a common pathophysiological mechanism. Dysfunctions in attentional and executive/top-down mechanisms are also common in both neurodegenerative and psychotic conditions, as are occipital cortex and HC involvement during hallucinations.

However, the differing predominance of auditory and visual modalities in neurodegenerative disease and psychosis, the phenomenological differences at the levels of emotional reactions and appraisals, and the differing dysconnectivity and visual processing profiles suggest there are also important differences. Perhaps the same pathological mechanism has differential effects on the visual and auditory systems in psychosis and neurodegenerative disease, depending on the presence/absence of specific co-occurring sensory dysfunctions. Such comparative insights have potentially important implications for treating VH as they provide a rationale for importing approaches found effective in one clinical context to another.

Treatment Approaches

Cognitive Behavioral Therapy

Cognitive behavioral therapy has an established, though modest, evidence base for the treatment of psychosis (referred to as CBTp). However, evidence for its use in VH rests mainly on case studies.

Recently, O'Brien and Johns¹⁰⁷ described an individual who had visions of snakes and who held beliefs that she

was at risk of harm from these snakes. CBT that included a graded exposure approach to help reduce fear and escape reaction showed some benefit which was maintained at 3 months. Whether this is helpful with other visual experiences is unclear, although studies show that the appraisals and beliefs should be a core target for treatment.^{70,108}

Collerton and Dudley¹⁰⁹ developed a model drawn from a cognitive model of auditory hallucinations and panic and which targets appraisal and reactions to VH. Given that avoidance, escape and safety-seeking behaviors are common but unhelpful strategies, the aim of treatment is for people to recognize that they are safe, and that the fear may be real but the danger is not. The therapy includes psychoeducation about VH, reality testing and normalization, as well as understanding of triggers. Imagery exposure and transformation strategies are used to attempt control over the experience. A case series (under review) describes the use of this treatment approach in 4 people with psychosis with distressing VH.

Overall, evidence for the effectiveness of CBT for VH is limited. The treatment of VH may be improved by addressing trauma and stress as a key feature of VH presentation, and with the development of sensitive and specific outcome measures that match the goals of treatment.

The Pharmacological Management of VH

There is limited evidence for specific pharmacological treatments for VH in psychosis. Antipsychotics are typically used, but some studies have reported that VHs were not linked to treatment effects^{28,110} or even that VHs may be a marker of neuroleptic resistance.¹⁰ Clozapine has been reported as effective for VH in PD,¹¹¹ but studies in schizophrenia are lacking.

The literature drawn from organic disease suggests the different approaches that might be considered. For example, for individuals with visual impairment, treatment of the eye condition can reduce the risk of VH.¹¹² The case report literature has highlighted a range of medications that may help reduce VH, but there is currently a lack of clinical trial data. For example, drugs increasing cholinergic activity are thought to reduce the risk for VH. The AchE-I (rivastigmine, donepezil, and galantamine) are beneficial when treating behavioral and psychological symptoms of dementia¹¹³ and PD¹¹⁴ and have been reported to help in schizophrenia.¹¹⁴ Other drugs have been used in organic conditions (antidepressants, memantine, or anticonvulsants) but have not been examined in psychosis.

In sum, there is a lack of systematic studies, but this overview suggests new possibilities for treating VH in psychosis.

Conclusion

Altogether, this article reviewed the available evidence on the prevalence, phenomenology, clinical characteristics,

Table 4. Future Directions

Future Studies Should Seek to Pursue the Following Research Questions	
i)	What is the frequency of VH in psychosis, as assessed using prospective, rigorous, and detailed investigations? What is the relationship of VH with hallucinations in other modalities (eg, temporal relationship, similarities in content and emotional themes)?
ii)	Are “fused” multimodality hallucinations characteristic of schizophrenia or do they occur in other disorders? Is there a close relationship between VH and voices in fused hallucinations, such that there is a match between the vision and the verbal output? Is the acoustic information closely linked to the speaker’s characteristics (sex, age, emotional characteristics)? Are there reports of fused hallucinations of animals (eg, dogs barking), and environmental scenes (eg, car with engine running, water falls), in addition to fused hallucinations of persons (person talking)?
iii)	What are the similarities and differences in the VH profile of individuals with psychosis compared with other psychiatric/neurological conditions at the level of phenomenological characteristics, risk factors, triggers, cognition, psychology, social and brain factors, as assessed using direct comparisons?
iv)	Are the same brain regions and networks activated during VH in psychosis also activated during VH in other conditions? Are the changes in brain structure, function, and connectivity predisposing to VH the same across different conditions?
v)	What are the mechanisms involved in hallucinations in different modalities? Is there a set of core pathological mechanisms in addition to specific modality-dependent dysfunctions? Alternatively, is there one pathological mechanism that has differential effects on visual and auditory systems?
vi)	What is the compatibility of verbal (language based) models of auditory hallucinations which focus on deviations in language areas, with models of <i>visual</i> hallucinations?
vii)	What are the mechanisms by which distress and negative mood contribute to both visual and auditory hallucinations?
viii)	What is the predictive value of non-clinical VH (especially for those first observed in childhood/adolescence), as assessed using longitudinal epidemiological study designs?
ix)	Are there different subtypes of VH and which type is most often associated with poorer prognosis and functioning?
x)	Research into the treatment for VH in individuals requiring care is urgently needed, examining the efficacy of existing and new interventions in large samples

Note: VH = visual hallucination.

assessment methods, cognition, brain imaging, electrophysiology, and treatment approaches for VH in the psychosis spectrum.

There are significant potential benefits to making direct comparisons of VH in organic and psychotic illness. These include informing our understanding and theoretical models

of VH in schizophrenia and across diagnostic categories, informing hypothesis-driven questions for research, and suggesting new possibilities for therapeutic interventions.

This is the first review of VH in psychosis to incorporate data using different methodological perspectives and different population groups. One open question is whether VHs in psychosis have the same pathological mechanisms as VH in eye or organic conditions. From the evidence, it is clear that they are not as closely associated as they might appear. They show some similarities in clinical presentation and form, and in cognitive mechanisms, but differences in age, emotional content and appraisal, pathological profile, and neuroimaging findings might argue for different causal pathways. There is also little evidence one way or the other on whether visual perception in psychosis is as impaired as it is in other disorders.

This review also aided our understanding of hallucinations across different modalities, and particularly auditory hallucinations. As seen above, auditory hallucinations and VH frequently co-occur, although not necessarily simultaneously. One possibility suggests a set of core pathological mechanisms in addition to specific modality-dependent dysfunctions. Alternatively, the same pathological mechanism has differential effects on the visual and auditory systems in psychosis and neurodegenerative disease, depending on the presence/absence of specific co-occurring sensory dysfunctions. Clearly, direct comparisons are needed testing the compatibility of theoretical models developed in the 2 modalities of hallucinations (see key future directions in [table 4](#)).

Funding

F.W. is supported by a National Health and Medical Research Grant (634329) and funding from North Metro Health Service Mental Health (Graylands Hospital).

Acknowledgment

The authors have declared that there are no conflicts of interest in relation to the subject of this study.

References

1. Macpherson F. The philosophy and psychology of hallucination: an introduction. In: Macpherson F, Platchias D, eds. *Hallucination: Philosophy and Psychology*. Cambridge, MA: MIT Press; 2013.
2. Bleuler E. *Textbook of Psychiatry*. Eds Brill. New York: Macmillan; 1924.
3. Waters F, Woods A, Fernyhough C. Report on the 2nd International Consortium on Hallucination Research (ICHR): evolving directions and top 10 ‘hot spot’ in hallucination research. *Schizophr Bull*. 2014;40: 24–27. doi: 10.1093/schbul/sbt167

4. Jablensky A, Sartorius N, Ernberg G, et al. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. *Psychol Med Monogr Suppl.* 1992;20:1–97.
5. Bowman K, Raymond A. A statistical study of delusions in the manic-depressive psychoses. *Am J Psychiatry.* 1931–1932;88:111–121.
6. Goodwin F, Jamison K. *Manic Depressive Illness.* Oxford: Oxford Press; 1999.
7. Feinberg I. A comparison of the visual hallucinations in schizophrenia with those induced by mescaline and LSD-25. *Hallucinations.* 1962:64–76.
8. Malitz S, Wilkins B, Esecover H. A comparison of drug-induced hallucinations with those seen in spontaneously occurring psychosis. In: West LJ, ed. *Hallucinations.* New York, NY: Grune & Stratton; 1962.
9. Vitols MM, Waters HG, Keeler MH. Hallucinations and delusions in white and negro schizophrenics. *Am J Psychiatry.* 1963;120:472–476.
10. Goldberg SC, Klerman GL, Cole JO. Changes in schizophrenic psychopathology and ward behaviour as a function of phenothiazine treatment. *Br J Psychiatry.* 1965;111:120–133.
11. Mott RH, Small IF, Anderson JM. Comparative study of hallucinations. *Arch Gen Psychiatry.* 1965;12:595–601.
12. Small IF, Small JG, Andersen JM. Clinical characteristics of hallucinations of schizophrenia. *Dis Nerv Syst.* 1966;27:349–353.
13. Chapman J. The early symptoms of schizophrenia. *Br J Psychiatry.* 1966;112:225–251.
14. Holmboe R, Astrup C. A follow-up study of 255 patients with acute schizophrenia and schizophreniform psychoses. *Acta Psychiatr Scand Suppl.* 1957;115:9–61.
15. Jansson B. The prognostic significance of various types of hallucinations in young people. *Acta Psychiatr Scand.* 1968;44:401–409.
16. Goodwin DW, Alderson P, Rosenthal R. Clinical significance of hallucinations in psychiatric disorders. A study of 116 hallucinatory patients. *Arch Gen Psychiatry.* 1971;24:76–80.
17. Eggers C. *Verlaufsweisen Kindlicher and Praepuberaler Schizophrenien. Monographie aus dem Gesamtgebiet der Psychiatrie V.* Berlin, Germany: Springer Verlag.
18. McCabe MS, Fowler RC, Cadoret RJ, Winokur G. Symptom differences in schizophrenia with good and poor prognosis. *Am J Psychiatry.* 1972;128:1239–1243.
19. Young B. A phenomenological comparison of LSD and schizophrenic states. *Br J Psychiatry.* 1974;124:64–74.
20. Zarroug E. The frequency of visual hallucinations in schizophrenic patients in Saudi Arabia. *Br J Psychiatry.* 1975;127:55–63.
21. Ciompi L, Müller C. *Lebensweg und Alter der Schizophrenen.* Berlin, Germany: Springer; 1976.
22. Deiker T, Chambers HE. Structure and content of hallucinations in alcohol withdrawal and functional psychosis. *J Stud Alcohol.* 1978;39:1831–1840.
23. Huber G, Gross G, Schüttler R. *Schizophrenie. Eine verlaufs- und sozialpsychiatrische Langzeitstudie.* Berlin, Germany: Springer; 1979.
24. Ndeti DM, Singh A. Hallucinations in Kenyan schizophrenic patients. *Acta Psychiatr Scand.* 1983;67:144–147.
25. Ndeti D, Vadher A. A cross-cultural study of the frequencies of Schneider's first rank symptoms of schizophrenia. *Acta Psychiatr Scand.* 1984;70:540–544.
26. Winokur G, Scharfetter C, Angst J. The diagnostic value in assessing mood congruence in delusions and hallucinations and their relationship to the affective state. *Eur Arch Psychiatry Neurol Sci.* 1985;234:299–302.
27. Phillipson O, Harris J. Hallucinations in schizophrenia. *Acta Psychiatr Scand.* 1985;82:26–29.
28. Bracha HS, Wolkowitz OM, Lohr JB, Karson CN, Bigelow LB. High prevalence of visual hallucinations in research subjects with chronic schizophrenia. *Am J Psychiatry.* 1989;146:526–528.
29. Owens RG, Slade PD, Fielding DM. Methods: patient series and quasi-experimental designs. In: Parry G, Watts FN, eds. *Behavioural and Mental Health Research: A Handbook of Skills and Methods.* Hove, UK: Lawrence Erlbaum Associates; 1989:189–210.
30. Mueser KT, Bellack AS, Brady EU. Hallucinations in schizophrenia. *Acta Psychiatr Scand.* 1990;82:26–29.
31. Bauer SM, Schanda H, Karakula H, et al. Culture and the prevalence of hallucinations in schizophrenia. *Compr Psychiatry.* 2011;52:319–325.
32. Rosenthal S. Changes in a population of hospitalised patients with affective disorders 1945–1965. *Am J Psychiatry.* 1966;123:671–681.
33. Taylor M, Abrams R. The phenomenology of mania: a new look at some old patients. *Arch Gen Psychiatry.* 1973;29:520–522.
34. Rosenthal NE, Rosenthal LN, Stallone F, Dunner DL, Fieve RR. Toward the validation of RDC schizoaffective disorder. *Arch Gen Psychiatry.* 1980;37:804–810.
35. Black DW, Nasrallah A. Hallucinations and delusions in 1,715 patients with unipolar and bipolar affective disorders. *Psychopathology.* 1988;22:28–34.
36. Keck PE Jr, McElroy SL, Havens JR, et al. Psychosis in bipolar disorder: phenomenology and impact on morbidity and course of illness. *Compr Psychiatry.* 2003;44:263–269.
37. Baethge C, Baldessarini R, Freudenthal K, Streeruwitz A. Hallucinations in bipolar disorder: characteristics and comparison to unipolar depression and schizophrenia. *Bipol Disord.* 2005;7:136–145.
38. Tillman R, Geller B, Klages T, Corrigan M, Bolhofner K, Zimmerman B. Psychotic phenomena in 257 young children and adolescents with bipolar I disorder: delusions and hallucinations (benign and pathological). *Bipolar Disord.* 2008;10:45–55.
39. Eaton WW, Romanoski A, Anthony JC, Nestadt G. Screening for psychosis in the general population with a self-report interview. *J Nerv Ment Dis.* 1991;179:689–693.
40. Tien AY. Distributions of hallucinations in the population. *Soc Psychiatry Psychiatr Epidemiol.* 1991;26:287–292.
41. Ohayon MM. Prevalence of hallucinations and their pathological associations in the general population. *Psychiatry Res.* 2000;97:153–164.
42. Waters FAV, Badcock JC, Maybery MT. Revision of the factor structure of the Launay-Slade Hallucination Scale (LSHS-R). *Pers Individ Dif.* 2003;35:1351–1357.
43. Laroï F, Van der Linden M. Non-clinical participants reports of hallucinatory experiences. *Can J Behav Sci.* 2003;37:33–43.
44. Kessler RC, Birnbaum H, Demler O, et al. The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R). *Biol Psychiatry.* 2005;58:668–676.
45. Van Os J, Hanssen M, Bijl RV. Strauss (1969) revisited: a psychosis continuum in the general population? *Schizophr Res.* 2000;45:11–20.

46. Núñez L, Gurpegui M. Cannabis-induced psychosis: a cross-sectional comparison with acute schizophrenia. *J Clin Psychiatry*. 2002;63:812–816.
47. Mitchell J, Vierkant AD. Delusions and hallucinations of cocaine abusers and paranoid schizophrenics: a comparative study. *J Psychol*. 1991;125:301–310.
48. Williams DR, Warren JD, Lees AJ. Using the presence of visual hallucinations to differentiate Parkinson's disease from atypical parkinsonism. *J Neurol Neurosurg Psychiatry*. 1998;1979:652–655.
49. Fénelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. *Brain*. 2000;123 (Pt 4):733–745.
50. Schadlu AP, Schadlu R, Shepherd JB 3rd. Charles Bonnet syndrome: a review. *Curr Opin Ophthalmol*. 2009;20:219–222.
51. ffytche DH. Visual hallucinations in eye disease. *Curr Opin Neurol*. 2009;22:28–35.
52. Lindal E, Stefansson G, Stefansson S. The qualitative difference of visions and visual hallucinations: a comparison of a general-population sample and clinical sample. *Compr Psychiatry*. 1994;35:405–408.
53. Lowe GR. The phenomenology of hallucinations as an aid to differential diagnosis. *Br J Psychiatry*. 1973;123:621–633.
54. Larøi F, DeFruyt F, van Os J, Aleman A, Van der Linden M. Associations between hallucinations and personality structure in a non-clinical sample: comparison between young and elderly samples. *Pers Individ Diff*. 2005;39:189–200.
55. Osis K, Haraldsson E. *At the Hour of Death*. New York, NY: Avon Books; 1977.
56. Schultz SK, Miller DD, Oliver SE, Arndt S, Flaum M, Andreasen NC. The life course of schizophrenia: age and symptom dimensions. *Schizophr Res*. 1997;23:15–23.
57. Oorschot M, Lataster T, Thewissen V, Wichers M, Myin-Germeyns I. Mobile assessment in schizophrenia: a data-driven momentary approach. *Schizophr Bull*. 2012;38:405–413.
58. Morrison AP, Wells A, Nothard S. Cognitive factors in predisposition to auditory and visual hallucinations. *Br J Clin Psychol*. 2000;39 (Pt 1):67–78.
59. Rees W. The hallucinations of widowhood. *Br Med J*. 1971;4:37–38.
60. Forsell Y. Predictors for depression, anxiety and psychotic symptoms in a very elderly population: data from a 3-year follow-up study. *Soc Psychiatry Psychiatr Epidemiol*. 2000;35:259–263.
61. Forsell Y, Henderson A. Epidemiology of paranoid symptoms in an elderly population. *Br J Psychiatry*. 1988;172:419–432.
62. Frieske DA, Wilson WP. Formal qualities of hallucinations: a comparative study of the visual hallucinations in patients with schizophrenic, organic, and affective psychoses. *Proc Annu Meet Am Psychopathol Assoc*. 1966;54:49–62.
63. Delespaul P, deVries M, van Os J. Determinants of occurrence and recovery from hallucinations in daily life. *Soc Psychiatry Psychiatr Epidemiol*. 2002;37:97–104.
64. Gauntlett-Gilbert J, Kuipers E. Phenomenology of visual hallucinations in psychiatric conditions. *J Nerv Ment Dis*. 2003;191:203–205.
65. Kelleher I, Harley M, Murtagh A, Cannon M. Are screening instruments valid for psychotic-like experiences? A validation study of screening questions for psychotic-like experiences using in-depth clinical interview. *Schizophr Bull*. 2011;37:362–369.
66. Deahl MP. Do patients see visions that talk? *Lancet*. 1987;1:812.
67. Fénelon G. Hallucinations in Parkinson's disease. In: Larøi FA, Aleman A, eds. *Hallucinations: A Guide to Treatment and Management*. Oxford: Oxford University Press; 2010.
68. Ballard C, Saad K, Patel A, et al. The prevalence and phenomenology of psychotic symptoms in dementia sufferers. *Int J Geriatr Psychiatry*. 1995;19:477–483.
69. Mosimann U, Collerton D. Hallucinations in the context of dementing illnesses. In: Frank Larøi AA, ed. *Hallucinations: A Guide to Treatment and Management*. 1st ed. Oxford: OUP; 2010.
70. Dudley R, Wood M, Spencer H, Brabban A, Mosimann UP, Collerton D. Identifying specific interpretations and use of safety behaviours in people with distressing visual hallucinations: an exploratory study. *Behav Cogn Psychother*. 2012;40:367–375.
71. Rosenthal D, Quinn OW. Quadruplet hallucinations. Phenotypic variations of a schizophrenic genotype. *Arch Gen Psychiatry*. 1977;34:817–827.
72. Asaad G, Shapiro B. Hallucinations: theoretical and clinical overview. *Am J Psychiatry*. 1986;143:1088–1097.
73. Chapman LJ, Edell WS, Chapman JP. Physical anhedonia, perceptual aberration, and psychosis proneness. *Schizophr Bull*. 1980;6:639–653.
74. Johns L, Kompus K, Connell M, et al. Auditory verbal hallucinations in persons with and without a need for care. *Schizophr Bull*. 2014;40:S255–S264.
75. ffytche DH. Visual hallucinations and the Charles Bonnet syndrome. *Curr Psychiatry Rep*. 2005;7:168–179.
76. Eperjesi F. Visual hallucinations in Charles Bonnet syndrome. In: Aleman FLA, ed. *Hallucinations: A Guide to Treatment and Management*. Oxford: Oxford University Press; 2010.
77. ffytche DH. Visual hallucinatory syndromes: past, present, and future. *Dialogues Clin Neurosci*. 2007;9:173–189.
78. Aleman A, Larøi F. *Hallucinations: The Science of Idiosyncratic Perception*. Washington, DC: American Psychological Association; 2008.
79. Blom JD. *A Dictionary of Hallucinations*. New York, NY: Springer Science + Business Media; 2010.
80. Collerton D, Perry E, McKeith I. Why people see things that are not there: a novel Perception and Attention Deficit model for recurrent complex visual hallucinations. *Behav Brain Sci*. 2005;28:737–757; discussion 757–794.
81. Diederich NJ, Fénelon G, Stebbins G, Goetz CG. Hallucinations in Parkinson disease. *Nat Rev Neurol*. 2009;5:331–342.
82. Shine JM, Halliday GM, Naismith SL, Lewis SJ. Visual misperceptions and hallucinations in Parkinson's disease: dysfunction of attentional control networks? *Mov Disord*. 2011;26:2154–2159.
83. Bentall RP, Baker GA, Havers S. Reality monitoring and psychotic hallucinations. *Br J Clin Psychol*. 1991;30 (Pt 3):213–222.
84. Brébion G, Ohlsen RI, Pilowsky LS, David AS. Visual hallucinations in schizophrenia: confusion between imagination and perception. *Neuropsychology*. 2008;22:383–389.
85. Waters F, Woodward T, Allen P, Aleman A, Sommer I. Self-recognition deficits in schizophrenia patients with auditory hallucinations: a meta-analysis of the literature. *Schizophr Bull*. 2012;38:741–750.
86. Jardri R, Thomas P, Delmaire C, Delion P, Pins D. The neurodynamic organization of modality-dependent hallucinations. *Cereb Cortex*. 2013;23:1108–1117.

87. Oertel V, Rotarska-Jagiela A, van de Ven VG, Haenschel C, Maurer K, Linden DE. Visual hallucinations in schizophrenia investigated with functional magnetic resonance imaging. *Psychiatry Res.* 2007;156:269–273.
88. Silbersweig D, Stern E. Functional neuroimaging of hallucinations in schizophrenia: toward an integration of bottom-up and top-down approaches. *Mol Psychiatry.* 1996;1:367–375.
89. Holroyd S, Shepherd ML, Downs JH 3rd. Occipital atrophy is associated with visual hallucinations in Alzheimer's disease. *J Neuropsychiatry Clin Neurosci.* 2000;12:25–28.
90. O'Brien JT, Colloby SJ, Pakrasi S, et al. Nicotinic alpha-4beta2 receptor binding in dementia with Lewy bodies using 123I-5IA-85380 SPECT demonstrates a link between occipital changes and visual hallucinations. *Neuroimage.* 2008;40:1056–1063.
91. Taylor JP, Firbank MJ, He J, et al. Visual cortex in dementia with Lewy bodies: magnetic resonance imaging study. *Br J Psychiatry.* 2012;200:491–498.
92. ffytche DH, Howard RJ, Brammer MJ, David A, Woodruff P, Williams S. The anatomy of conscious vision: an fMRI study of visual hallucinations. *Nat Neurosci.* 1998;1:738–742.
93. Diederich NJ, Fénelon G, Stebbins G, Goetz CG. Hallucinations in Parkinson disease. *Nat Rev Neurol.* 2009;5:331–342.
94. Holroyd S, Wooten GF. Preliminary FMRI evidence of visual system dysfunction in Parkinson's disease patients with visual hallucinations. *J Neuropsychiatry Clin Neurosci.* 2006;18:402–404.
95. Stebbins GT, Goetz CG, Carrillo MC. Altered cortical visual processing in PD with hallucinations: an fMRI study. 2004;63:1409–1416.
96. Goldman JG, Stebbins GT, Dinh V, et al. Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations. *Brain.* 2014;137(Pt3):849–859.
97. Amad A, Cachia A, Gorwood P, et al. The multimodal connectivity of the hippocampal complex in auditory and visual hallucinations. *Mol Psychiatry.* 2014;19:184–191.
98. Ashtari M, Cottone J, Ardekani BA, et al. Disruption of white matter integrity in the inferior longitudinal fasciculus in adolescents with schizophrenia as revealed by fiber tractography. *Arch Gen Psychiatry.* 2007;64:1270–1280.
99. Ibarretxe-Bilbao N, Ramírez-Ruiz B, Tolosa E, et al. Hippocampal head atrophy predominance in Parkinson's disease with hallucinations and with dementia. *J Neurol.* 2008;255:1324–1331.
100. Behrendt RP. Contribution of hippocampal region CA3 to consciousness and schizophrenic hallucinations. *Neurosci Biobehav Rev.* 2010;34:1121–1136.
101. Allen P, Modinos G, Hubl D, et al. Neuroimaging auditory hallucinations in schizophrenia: from neuroanatomy to neurochemistry and beyond. *Schizophr Bull.* 2012;38:695–703.
102. Spencer KM, Nestor PG, Perlmutter R, et al. Neural synchrony indexes disordered perception and cognition in schizophrenia. *Proc Natl Acad Sci U S A.* 2004;101:17288–17293.
103. Matsui H, Udaka F, Tamura A, et al. The relation between visual hallucinations and visual evoked potential in Parkinson disease. *Clin Neuropharmacol.* 2005;28:79–82.
104. Abraham HD, Duffy FH. EEG coherence in post-LSD visual hallucinations. *Psychiatry Res.* 2001;107:151–163.
105. ffytche DH. The hodology of hallucinations. *Cortex.* 2008;44:1067–1083.
106. Kazui H, Ishii R, Yoshida T. Neuroimaging studies in patients with Charles Bonnet syndrome. *Psychogeriatrics.* 2009;9:77–84.
107. O'Brien P, Johns L. A graded exposure intervention for distressing visual hallucinations in schizophrenia. *Behav Cogn Psychother.* 2013;3:45–46.
108. Gauntlett-Gilbert J, Kuipers E. Visual hallucinations in psychiatric conditions: appraisals and their relationship to distress. *Br J Clin Psychol.* 2005;44:77–87.
109. Collerton D, Dudley R. A cognitive behavioural framework for the treatment of distressing visual hallucinations in older people. *Behav Cogn Psychother.* 2004;32:443–455.
110. Cuesta MJ, Peralta V, Zarzuela A. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. *Schizophr Res.* 2001;48:17–28.
111. The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. *N Engl J Med.* 1999;340:757–763.
112. Singh A, Sørensen TL. Charles Bonnet syndrome improves when treatment is effective in age-related macular degeneration. *Br J Ophthalmol.* 2011;95:291–292.
113. Pinto T, Lanctôt KL, Herrmann N. Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer's type. *Ageing Res Rev.* 2011;10:404–412.
114. Patel SS, Attard A, Jacobsen P, Shergill S. Acetylcholinesterase Inhibitors (AChEI's) for the treatment of visual hallucinations in schizophrenia: a case report. *BMC Psychiatry.* 2010;10:68.